-
hiPSC Intestinal Organoids for Pharmacokinetics
2026-09-12
Saito and colleagues developed a direct three-dimensional cluster-culture strategy for generating expandable intestinal organoids from human induced pluripotent stem cells. The resulting organoids could be propagated, cryopreserved, and converted into epithelial monolayers containing functionally relevant enterocytes for studying intestinal drug metabolism and transport.
-
Novel Allosteric PDK4 Inhibitors for Metabolic Disease
2026-09-12
The 2019 Journal of Medicinal Chemistry study identified anthraquinone-derived allosteric inhibitors of pyruvate dehydrogenase kinase 4, with compound 8c showing 84 nM in vitro potency and activity in metabolic, allergic, and cancer-related models. Its integrated medicinal chemistry, pharmacokinetic, docking, and animal-study strategy provides a useful framework for evaluating PDK4-directed scaffolds while highlighting the limits of translating preclinical metabolic findings.
-
BMN 673: PARP Trapping Meets Splicing Biology
2026-09-11
BMN 673 (Talazoparib) combines sub-nanomolar PARP1/2 inhibition with strong PARP–DNA complex trapping. This article explains how spliceosome-controlled DNA repair states could reshape DNA repair deficiency targeting and assay design in cancer research.
-
EPZ5676: A Practical DOT1L Inhibitor Workflow
2026-09-11
Build reproducible DOT1L inhibition, H3K79 methylation, and leukemia cell-response assays with EPZ5676. This guide connects biochemical potency to MLL-rearranged leukemia workflows while adapting immune-signature lessons from melanoma epigenetic research without overstating cross-disease evidence.
-
TH287 Radiosensitizes Castration-Resistant Prostate Cancer
2026-09-10
A 2026 study found that combining the MTH1 inhibitor TH287 with ionizing radiation reduced survival and increased apoptosis in PC-3 and DU-145 castration-resistant prostate cancer cells. The strongest effect occurred when radiation was delivered 12 hours after TH287 exposure, highlighting treatment sequence as an important variable in radiosensitization studies.
-
Gramine for TNBC Ferroptosis Research
2026-09-10
Gramine is a research-grade ferroptosis inducer for connecting TNBC viability loss with CUL3–MTDH signaling, ubiquitination, and lipid-peroxidation readouts. This workflow emphasizes fresh solution preparation, orthogonal target validation, rescue experiments, and troubleshooting for reproducible cancer biology research.
-
SAR131675: VEGFR-3 Inhibitor Workflow Guide
2026-09-09
Build robust VEGFR-3 assays with SAR131675 by connecting biochemical potency to receptor phosphorylation, lymphatic endothelial phenotypes, angiogenesis, and macrophage biology. This workflow also highlights formulation constraints, pathway-specific controls, and the translational limits of hepatic fibrosis and tumor models.
-
L-Threonine in ALP Assay Design
2026-09-09
L-Threonine is not merely a culture supplement: it is a controllable metabolic variable that can shape interpretation of alkaline phosphatase experiments. This guide connects threonine handling, metabolic profiling, and the mechanistic advantages of metal-free carbon-dot nanozyme assays.
-
Dimethyloxalylglycine (DMOG) Protocol Guide
2026-09-08
Dimethyloxalylglycine (DMOG), SKU A4506, provides a controlled chemical approach for hypoxia-inducible factor stabilization in cell-based oxygen-sensing, hypoxia signaling, and inflammation studies. This guide covers preparation, controls, and interpretation boundaries; the compound is for scientific research only and should not be used as a diagnostic, therapeutic, or universal in vivo dosing reagent.
-
FITC Goat Anti-Mouse IgG (H+L) Antibody
2026-09-08
A scenario-driven guide to selecting, handling, and interpreting FITC-based mouse IgG detection in immunofluorescence and flow cytometry. It explains how SKU K1201 can support reproducible phenotyping alongside cell viability, proliferation, and cytotoxicity assays.
-
Batimastat (BB-94): Reliable MMP Assays
2026-09-07
Learn how Batimastat (BB-94), SKU A2577, can help researchers distinguish MMP-dependent extracellular effects from nonspecific cytotoxicity in viability, invasion, tumor, and neuromuscular assays. The article connects quantitative potency, solvent handling, controls, and interpretation to practical laboratory decisions.
-
Protease Inhibitor Cocktail: Workflow Guide
2026-09-05
Protect labile proteins, phosphosignals, and protein complexes during cell and tissue disruption with an EDTA-free, broad-spectrum formulation. This guide translates a recent PCNSL single-cell study into practical extraction, immunoprecipitation, kinase-assay, and troubleshooting workflows.
-
Tanshinone IIA Pathways in Psoriasis: Study Insights
2026-09-05
This study combines network pharmacology, molecular docking, keratinocyte assays, and an imiquimod-induced mouse model to explain how tanshinone IIA from Xiao-Yin decoction may suppress psoriasis-associated inflammation. Its central contribution is linking IL-17/IL-23 signaling with the PTGS2/NF-κB/AP-1 axis and showing stronger pathway inhibition when tanshinone IIA is combined with methotrexate.
-
Diuron as a Translational Toxicology Probe
2026-09-04
Diuron is more than a photosynthesis inhibitor: it is a useful probe for connecting exposure chemistry, plant biology research, and emerging renal toxicology evidence. This article presents an evidence-centered framework for choosing assays and interpreting JAK2/STAT1-related findings without conflating biological systems.
-
PGF2α/PTGFR in Endometrial Breakdown
2026-09-04
A 2024 mouse menstrual-like model study identifies PGF2α/PTGFR as a major regulator of endometrial breakdown and vascular permeability after progesterone withdrawal. Its combination of pharmacological inhibition, vascular readouts, and HIF-1α promoter analysis links prostaglandin signaling to a defined transcriptional mechanism with relevance to menstrual biology.